Pivotal bioVenture Partners Fund I, L.P.

13D and 13G Filings

13D/G filings: 13D on 2 securities, 13G on 2 securities
Location: Grand Cayman, Cayman Islands
CIK: 0001695076
Alternate names: Pivotal Venture Partners Fund I, L.P.
Form D filings: 3 filings
All SEC filings: View on sec.gov

Issuer	Symbol	CUSIP	% of Class	Shares	Form	Filed
Bolt Biotherapeutics, Inc. 13D/A Amendment 4 BOLT · 097702203	BOLT	097702203	4.6%	87,486	13D/A Amendment 4	2/26/2026 Event 2/24/2026
Nan Fung Group Holdings Limited			4.6%	87,486
NF Investment Holdings Limited			4.6%	87,486
Pivotal bioVenture Partners Fund I, L.P.			2.7%	52,556
Pivotal bioVenture Partners Fund I G.P., L.P.			2.7%	52,556
Pivotal bioVenture Partners Fund I U.G.P. Ltd.			2.7%	52,556
Pivotal Partners Ltd			2.7%	52,556
Pivotal Life Sciences Holdings Limited			2.7%	52,556
Nan Fung Life Sciences Holdings Limited			4.3%	82,486
Permwell Management Limited			0.3%	5,000
NFLS Beta Limited			1.6%	29,930
NFLS Platform Holdings Limited			1.6%	29,930
Bolt Biotherapeutics, Inc. 13D/A Amendment 3 BOLT · 097702203	BOLT	097702203	6.7%	128,119	13D/A Amendment 3	2/17/2026 Event 2/5/2026
Nan Fung Group Holdings Limited			6.7%	128,119
NF Investment Holdings Limited			6.7%	128,119
Pivotal bioVenture Partners Fund I, L.P.			4.1%	78,445
Pivotal bioVenture Partners Fund I G.P., L.P.			4.1%	78,445
Pivotal bioVenture Partners Fund I U.G.P. Ltd.			4.1%	78,445
Pivotal Partners Ltd			4.1%	78,445
Pivotal Life Sciences Holdings Limited			4.1%	78,445
Nan Fung Life Sciences Holdings Limited			6.4%	123,119
Permwell Management Limited			0.3%	5,000
NFLS Beta Limited			2.3%	44,674
NFLS Platform Holdings Limited			2.3%	44,674
Evommune, Inc. 13G EVMN · 30054Y107	EVMN	30054Y107	10.9%	3,435,599	13G	2/13/2026 Event 12/31/2025
Nan Fung Group Holdings Limited			10.9%	3,435,599
NF Investment Holdings Limited			10.7%	3,367,975
Nan Fung Life Sciences Holdings Limited			10.7%	3,367,975
NFLS Platform Holdings Limited			4.6%	1,441,032
NFLS Delta III Limited			4.6%	1,441,032
Pivotal Life Sciences Holdings Limited			6.1%	1,926,943
Pivotal Partners Ltd			6.1%	1,926,943
Pivotal bioVenture Partners Fund I U.G.P. Ltd.			5.2%	1,632,441
Pivotal bioVenture Partners Fund I G.P., L.P.			5.2%	1,632,441
Pivotal bioVenture Partners Fund I, L.P.			5.2%	1,632,441
Pivotal bioVenture Partners Fund II G.P. Ltd			0.9%	294,502
Pivotal bioVenture Partners Fund II, L.P.			0.9%	294,502
NFLS Delta Limited			4.6%	1,441,032
Oculis Holding AG 13G/A Amendment 1 OCS · H5870P102	OCS	H5870P102	4.9%	2,815,476	13G/A Amendment 1	11/14/2025 Event 9/30/2025
Nan Fung Group Holdings Limited			4.9%	2,815,476
NF Investment Holdings Limited			4.9%	2,815,476
Nan Fung Life Sciences Holdings Limited			4.9%	2,815,476
NFLS Platform Holdings Limited			0.9%	514,702
NFLS Beta Limited			0.9%	514,702
Pivotal Life Sciences Holdings Limited			4.0%	2,300,774
Pivotal Partners Ltd			4.0%	2,300,774
Pivotal bioVenture Partners Fund I U.G.P. Ltd.			4.0%	2,300,774
Pivotal bioVenture Partners Fund I G.P., L.P.			4.0%	2,300,774
Pivotal bioVenture Partners Fund I, L.P.			4.0%	2,300,774
Inozyme Pharma, Inc. 13D/A Amendment 5 INZY · 45790W108	INZY	45790W108	0%	0	13D/A Amendment 5	8/27/2025 Event 7/1/2025
Pivotal bioVenture Partners Fund I, L.P.			0%	0
Pivotal bioVenture Partners Fund II, L.P.			0%	0
Pivotal bioVenture Partners Fund II G.P. Ltd			0%	0
Pivotal bioVenture Partners Fund I G.P., L.P.			0%	0
Pivotal bioVenture Partners Fund I U.G.P. Ltd			0%	0
Pivotal Partners Ltd			0%	0
Pivotal Life Sciences Holdings Limited			0%	0
Nan Fung Life Sciences Holdings Limited			0%	0
NF Investment Holdings Limited			0%	0
Nan Fung Group Holdings Limited			0%	0

Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.